arrow
J

Jihad Kaouk

Glickman Urological Institute
H指数:95
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prostate cancer worldwide: updated epidemiology, disparities, and screening implications

前列腺癌全球现状:更新后的流行病学、差异及筛查意义

2026-10-270
OAAI
Cribriform and intraductal carcinoma in prostate cancer — implications for risk stratification and therapeutic decision-making

筛状和导管内癌在前列腺癌中的风险分层和治疗决策意义

2026-10-090
PRE
Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology

Gleason评分组1级前列腺癌伴最终病理pT3a病变患者的长期肿瘤学结局

2026-07-170
OAAI
Defining standards for retroperitoneal single-port (SP) robotic surgery: the Advancing Retroperitoneal International SP Excellence (ARISE) international Delphi consensus

制定腹膜后单孔(SP)机器人手术的标准:腹膜后单孔卓越国际推进(ARISE)国际德尔菲共识

2026-03-160
PRE
Single-port transvesical enucleation of the prostate (STEP) for benign prostatic hyperplasia: a comparative analysis of patients with large (80–150cc) and very large (>150cc) prostate volumes

经单孔经膀胱前列腺剜除术(STEP)治疗良性前列腺增生:大体积(80~150cc)和超大体积(>150cc)前列腺患者的比较分析

2026-02-210
OAAI
Short- and Long-term Functional Outcomes in a Large Cohort of Partial Nephrectomy Patients Managed with Prolonged Ischemia

长时间缺血条件下管理的大规模部分肾切除术患者短期和长期功能结局

2026-02-011
PRE
Safety of Partial and Radical Nephrectomy for Complex Locally Advanced Renal Cell Carcinoma After Neo-Adjuvant Immune Checkpoint Inhibition: Analysis From a Phase 1b Trial (Durvalumab plus /- Tremelimumab)

部分及根治性肾切除术治疗复杂局部晚期肾细胞癌的安全性(新辅助免疫检查点抑制剂治疗后):一项1b期试验(Durvalumab plus /- Tremelimumab)的分析

2025-10-010
PRE
The current landscape of single-port robotic surgery in urology

泌尿外科单端口机器人手术的当前现状

2025-09-020
PRE
Incidental prostate carcinoma after single-port robot-assisted simple prostatectomy: a multi-institutional report (SPARC)
2024-09-011
PRE
Limitations of Parenchymal Volume Analysis for Estimating Split Renal Function and New Baseline Glomerular Filtration Rate After Radical Nephrectomy

肾实质容积分析评估根治性肾切除术后分裂肾功能和新的基线肾小球滤过率的局限性

2024-06-016
PRE